To read the full story, subscribe or sign in.

Beone sells off Amgen Imdelltra royalties for $950M

Aug. 26, 2025

Beone Medicines Ltd. (formerly Beigene Ltd.) is selling its worldwide royalty rights on Imdelltra (tarlatamab) sales, excluding China, to Royalty Pharma for up to $950 million.

BioWorld BioWorld Asia Deals and M&A Cancer Cell therapy Asia-Pacific Europe U.S.

Today's news in brief

BioWorld

BioWorld briefs for April 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

A free gene therapy? Regeneron’s Otarmeni approved for hearing loss

BioWorld

Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...